Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of imgatuzumab for bowel cancer that has spread to another part of the body
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a drug called imgatuzumab for people with bowel cancer that had spread to other parts of the body (advanced bowel cancer).
More about this trial
- folinic acid
Summary of results
- imgatuzumab and FOLFIRI (group 1)
- cetuximab and FOLFIRI (group 2)
- imgatuzumab and FOLFIRI (group 3)
- FOLFIRI alone (group 4)
- seven months for group 1
- six months for group 2
- five months for group 3
- four months for group 4
- skin rash
- low levels of magnesium in the blood
- an increased risk of infection (neutropenia)
How to join a clinical trial
Experimental Cancer Medicine Centre (ECMC)
F. Hoffmann - La Roche